The Clorox Company (NYSE:CLX) Shares Sold by Signet Investment Advisory Group Inc.

Signet Investment Advisory Group Inc. cut its position in The Clorox Company (NYSE:CLX) by 2.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,029 shares of the company’s stock after selling 85 shares during the quarter. Signet Investment Advisory Group Inc.’s holdings in Clorox were worth $654,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Mizuho Securities USA LLC boosted its stake in shares of Clorox by 46,877.8% in the third quarter. Mizuho Securities USA LLC now owns 4,500,000 shares of the company’s stock valued at $733,095,000 after purchasing an additional 4,490,421 shares during the period. Ilex Capital Partners UK LLP lifted its holdings in Clorox by 512.7% during the 3rd quarter. Ilex Capital Partners UK LLP now owns 542,110 shares of the company’s stock worth $88,315,000 after buying an additional 453,624 shares in the last quarter. International Assets Investment Management LLC boosted its position in Clorox by 424.9% in the 3rd quarter. International Assets Investment Management LLC now owns 538,576 shares of the company’s stock valued at $877,390,000 after buying an additional 435,971 shares during the period. Boston Trust Walden Corp grew its stake in shares of Clorox by 5,442.5% in the third quarter. Boston Trust Walden Corp now owns 273,908 shares of the company’s stock worth $44,622,000 after acquiring an additional 268,966 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Clorox by 302.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 353,367 shares of the company’s stock worth $57,390,000 after acquiring an additional 265,455 shares during the period. 78.53% of the stock is owned by institutional investors and hedge funds.

Clorox Stock Performance

NYSE CLX opened at $148.47 on Wednesday. The company has a fifty day moving average of $160.68 and a two-hundred day moving average of $159.16. The company has a market capitalization of $18.38 billion, a PE ratio of 40.56, a P/E/G ratio of 2.52 and a beta of 0.42. The Clorox Company has a 1 year low of $127.60 and a 1 year high of $171.37. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.62.

Clorox (NYSE:CLX) last announced its earnings results on Monday, February 3rd. The company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.16. Clorox had a return on equity of 316.87% and a net margin of 6.38%. During the same period in the previous year, the firm posted $2.16 earnings per share. As a group, analysts expect that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 29th will be issued a $1.22 dividend. The ex-dividend date of this dividend is Wednesday, January 29th. This represents a $4.88 dividend on an annualized basis and a dividend yield of 3.29%. Clorox’s payout ratio is 133.33%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on CLX shares. Barclays lifted their target price on Clorox from $130.00 to $140.00 and gave the company an “underweight” rating in a report on Wednesday, February 5th. DA Davidson decreased their price objective on Clorox from $171.00 to $169.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Wells Fargo & Company upped their target price on shares of Clorox from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 4th. Evercore ISI lifted their price target on shares of Clorox from $145.00 to $155.00 in a research note on Tuesday, February 4th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Clorox from $171.00 to $173.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $158.21.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.